regardless of promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from PBMs. The organizations are typically building obstacles to reimbursement, like high cost restrictions and PA that hinder patient opportunity. Industry suggest that the